Literature DB >> 11282264

Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.

S Ioannidou1, P T Tassios, A Kotsovili-Tseleni, M Foustoukou, N J Legakis, A Vatopoulos.   

Abstract

A total of 200 isolates of viridans group streptococci isolated from the oropharynx of healthy Greek children were studied. Vancomycin, rifampicin, fluoroquinolones and dalfopristin/quinupristin were active against all tested isolates. High level resistance to gentamicin was not seen. Intermediate and high-level penicillin resistance was present in 28.5 and 14.5% isolates, respectively, with 41.3% of the latter group, being also resistant to cefotaxime. Resistance rates to other antimicrobials were as follows - erythromycin 38.5%, clarithromycin 33.5%, clindamycin 7.5% and tetracycline 23%. Penicillin resistance occurred more frequently in Streptococcus mitis isolates, while macrolide resistance was more frequent in S. oralis. MLSB resistance phenotype M was dominant (74%) among erythromycin resistant isolates, with phenotypes IR and CR being represented by 6 and 20% of isolates, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282264     DOI: 10.1016/s0924-8579(00)00338-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  The macrolide efflux genetic assembly of Streptococcus pneumoniae is present in erythromycin-resistant Streptococcus salivarius.

Authors:  Christina Stadler; Michael Teuber
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori.

Authors:  Xiao-Feng Luo; Jian-Hua Jiao; Wen-Yue Zhang; Han-Ming Pu; Bao-Jin Qu; Bing-Ya Yang; Min Hou; Min-Jun Ji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Highly penicillin-resistant multidrug-resistant pneumococcus-like strains colonizing children in Oeiras, Portugal: genomic characteristics and implications for surveillance.

Authors:  Alexandra S Simões; Raquel Sá-Leão; Marc J Eleveld; Débora A Tavares; João A Carriço; Hester J Bootsma; Peter W M Hermans
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

4.  Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae.

Authors:  Paula Cerdá Zolezzi; Leticia Millán Laplana; Carmen Rubio Calvo; Pilar Goñi Cepero; Melisa Canales Erazo; Rafael Gómez-Lus
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Osteomyelitis of the jaw: resistance to clindamycin in patients with prior antibiotics exposure.

Authors:  C Pigrau; B Almirante; D Rodriguez; N Larrosa; S Bescos; G Raspall; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-17       Impact factor: 3.267

6.  Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers.

Authors:  M Eisenblätter; C Klaus; M W R Pletz; H Orawa; H Hahn; J Wagner; H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-30       Impact factor: 3.267

7.  Disease isolates of Streptococcus pseudopneumoniae and non-typeable S. pneumoniae presumptively identified as atypical S. pneumoniae in Spain.

Authors:  Dora Rolo; Alexandra S Simões; Arnau Domenech; Asunción Fenoll; Josefina Liñares; Hermínia de Lencastre; Carmen Ardanuy; Raquel Sá-Leão
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 8.  Mechanisms of action of systemic antibiotics used in periodontal treatment and mechanisms of bacterial resistance to these drugs.

Authors:  Geisla Mary Silva Soares; Luciene Cristina Figueiredo; Marcelo Faveri; Sheila Cavalca Cortelli; Poliana Mendes Duarte; Magda Feres
Journal:  J Appl Oral Sci       Date:  2012 May-Jun       Impact factor: 2.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.